You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
|
|---|---|
| Published in |
Journal of Translational Medicine, August 2017
|
| DOI | 10.1186/s12967-017-1278-5 |
| Pubmed ID | |
| Authors |
Paolo A. Ascierto, Grant A. McArthur |
| Abstract |
Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in combination with other cancer treatments. In addition, recent research has shown that immune-based therapy can be used as adjuvant therapy, that outcomes may be influenced by dose, and that clinical activity is observed in patients with brain metastases. Despite our increased understanding of these agents, there are still several important questions that need to be answered. These include strategies to overcome primary and acquired resistance, the influence of mutational status on treatment outcomes, the optimal duration of treatment, and the need to identify novel combination regimens that offer increased anti-tumour potency and/or reduced toxicity. Here we review recent developments in these areas, with particular focus on new data reported at the 2017 ASCO Annual Meeting. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 2 | 22% |
| United States | 1 | 11% |
| Romania | 1 | 11% |
| Australia | 1 | 11% |
| Portugal | 1 | 11% |
| Unknown | 3 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 78% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 33% |
| Student > Bachelor | 7 | 15% |
| Student > Doctoral Student | 4 | 9% |
| Student > Master | 3 | 7% |
| Professor | 2 | 4% |
| Other | 4 | 9% |
| Unknown | 11 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 26% |
| Agricultural and Biological Sciences | 6 | 13% |
| Biochemistry, Genetics and Molecular Biology | 5 | 11% |
| Nursing and Health Professions | 4 | 9% |
| Immunology and Microbiology | 3 | 7% |
| Other | 4 | 9% |
| Unknown | 12 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 August 2017.
All research outputs
#4,167,592
of 23,630,563 outputs
Outputs from Journal of Translational Medicine
#679
of 4,190 outputs
Outputs of similar age
#71,679
of 318,627 outputs
Outputs of similar age from Journal of Translational Medicine
#8
of 51 outputs
Altmetric has tracked 23,630,563 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,190 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,627 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.